Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2009

Cordex Pharma Taps Cato to Undertake  Clinical Research

  • Cordex Pharma has employed Cato BioVentures to perform regulatory services and oversight of clinical testing of its products.

    Under the agreement, a portion of Cato's compensation for rendered services will be in the form of Cordex equity.

    Initially, the collaboration will focus on Cordex' Phase III trial with ATPace for the treatment of paroxysmal supraventricular tachycardia (PSVT). ATPace is a stable formulation of adenosine 5'-triphosphate administered by intravenous injection for the acute termination of PSVT.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »